Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviewsBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7161.771 (Published 19 September 1998) Cite this as: BMJ 1998;317:771
- Gerard Silvestri (), assistant professora,
- Robert Pritchard, assistant professorb,
- H Gilbert Welch, associate professorc
- aDivision of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC 29425-2220, USA
- bSection of Hematology/Oncology, Department of Veterans Affairs Medical Center, White River Junction, VT 05009, USA
- cVA Outcomes Group (111B), Department of Veterans Affairs Medical Center, White River Junction, VT 05009, USA
- Correspondence to: Dr Silvestri
- Accepted 2 June 1998
Objective:To determine how patients with lung cancer value the trade off between the survival benefit of chemotherapy and its toxicities.
Design:Scripted interviews that included three hypothetical scenarios. Each scenario described the same patient with metastatic non-small cell lung cancer with an expected survival of 4 months without treatment. Subjects were asked to indicate the minimum survival benefit required to accept the side effects of chemotherapy in the first two scenarios (mild toxicity and severe toxicity). In the third scenario, subjects were asked to choose between chemotherapy and supportive care when the benefit of chemotherapy was either to prolong life by 3 months or to palliate symptoms.
Subjects:81 patients previously treated with cis-platinum based chemotherapy for advanced non-small cell lung cancer.
Main outcome measure:Survival threshold for accepting chemotherapy.
Results:The minimum survival threshold for accepting the toxicity of chemotherapy varied widely in patients. Several patients would accept chemotherapy for a survival benefit of 1 week, while others would not choose chemotherapy even for a survival benefit of 24 months. The median survival threshold for accepting chemotherapy was 4.5 months for mild toxicity and 9 months for severe toxicity. When given the choice between supportive care and chemotherapy only 18 (22%) patients chose chemotherapy for a survival benefit of 3 months; 55 (68%) patients chose chemotherapy if it substantially reduced symptoms without prolonging life.
Conclusions:Patients' willingness to accept chemotherapy for the treatment of metastatic lung cancer varies widely. Many would not choose chemotherapy for its likely survival benefit of 3 months but would if it improved quality of life. The conflict between these patients' preferences and the care they previously received has several explanations, one being that some patients had not received the treatment they would have chosen had they been fully informed.
Contributors GS and RP conceived and designed the study, conducted the interviews, and wrote the paper. HGW designed the study, analysed the data, and wrote the paper; he will act as guarantor for the paper.
- Accepted 2 June 1998